BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24666736)

  • 1. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice.
    Tan CP; Feng Y; Zhou YP; Eiermann GJ; Petrov A; Zhou C; Lin S; Salituro G; Meinke P; Mosley R; Akiyama TE; Einstein M; Kumar S; Berger JP; Mills SG; Thornberry NA; Yang L; Howard AD
    Diabetes; 2008 Aug; 57(8):2211-9. PubMed ID: 18477808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats.
    Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K
    J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPR40 protein levels are crucial to the regulation of stimulated hormone secretion in pancreatic islets. Lessons from spontaneous obesity-prone and non-obese type 2 diabetes in rats.
    Meidute Abaraviciene S; Muhammed SJ; Amisten S; Lundquist I; Salehi A
    Mol Cell Endocrinol; 2013 Dec; 381(1-2):150-9. PubMed ID: 23911664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro.
    Verma MK; Biswas S; Chandravanshi B; Neelima K; Oommen AM; Jagannath MR; Somesh BP
    BMC Res Notes; 2014 Sep; 7():595. PubMed ID: 25186493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of GPR40 attenuates chronic inflammation induced impact on pancreatic β-cells health and function.
    Verma MK; Sadasivuni MK; Yateesh AN; Neelima K; Mrudula S; Reddy M; Smitha R; Biswas S; Chandravanshi B; Pallavi PM; Oommen AM; Jagannath MR; Somesh BB
    BMC Cell Biol; 2014 Jun; 15():24. PubMed ID: 24974801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
    Ueno H; Ito R; Abe SI; Ookawara M; Miyashita H; Ogino H; Miyamoto Y; Yoshihara T; Kobayashi A; Tsujihata Y; Takeuchi K; Watanabe M; Yamada Y; Maekawa T; Nishigaki N; Moritoh Y
    J Pharmacol Exp Ther; 2019 Aug; 370(2):172-181. PubMed ID: 31182471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice.
    Nagasumi K; Esaki R; Iwachidow K; Yasuhara Y; Ogi K; Tanaka H; Nakata M; Yano T; Shimakawa K; Taketomi S; Takeuchi K; Odaka H; Kaisho Y
    Diabetes; 2009 May; 58(5):1067-76. PubMed ID: 19401434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
    Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
    J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulinotropic effects of GPR120 agonists are altered in obese diabetic and obese non-diabetic states.
    Zhang D; So WY; Wang Y; Wu SY; Cheng Q; Leung PS
    Clin Sci (Lond); 2017 Feb; 131(3):247-260. PubMed ID: 27980130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents.
    Lin DC; Zhang J; Zhuang R; Li F; Nguyen K; Chen M; Tran T; Lopez E; Lu JY; Li XN; Tang L; Tonn GR; Swaminath G; Reagan JD; Chen JL; Tian H; Lin YJ; Houze JB; Luo J
    PLoS One; 2011; 6(11):e27270. PubMed ID: 22087278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40.
    Schnell S; Schaefer M; Schöfl C
    Mol Cell Endocrinol; 2007 Jan; 263(1-2):173-80. PubMed ID: 17101212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aqueous extract of tamarind seeds selectively increases glucose transporter-2, glucose transporter-4, and islets' intracellular calcium levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes mellitus.
    Sole SS; Srinivasan BP
    Nutr Res; 2012 Aug; 32(8):626-36. PubMed ID: 22935346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells.
    Kim HS; Hwang YC; Koo SH; Park KS; Lee MS; Kim KW; Lee MK
    PLoS One; 2013; 8(1):e50128. PubMed ID: 23372643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta-cells, isolated pancreatic islets and mice.
    McKillop AM; Moran BM; Abdel-Wahab YH; Flatt PR
    Br J Pharmacol; 2013 Nov; 170(5):978-90. PubMed ID: 23992544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids.
    Del Guerra S; Bugliani M; D'Aleo V; Del Prato S; Boggi U; Mosca F; Filipponi F; Lupi R
    Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):22-5. PubMed ID: 19758793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models.
    Guo DY; Li DW; Ning MM; Dang XY; Zhang LN; Zeng LM; Hu YH; Leng Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):740-7. PubMed ID: 26417688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules.
    Briscoe CP; Peat AJ; McKeown SC; Corbett DF; Goetz AS; Littleton TR; McCoy DC; Kenakin TP; Andrews JL; Ammala C; Fornwald JA; Ignar DM; Jenkinson S
    Br J Pharmacol; 2006 Jul; 148(5):619-28. PubMed ID: 16702987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.